Document is current

Article History

Received: 15 March 2025

Revised: 7 June 2025

Accepted: 30 June 2025

First Online: 10 July 2025

Declarations

:

: Ruiz: Serves as a consultant Regeneron Inc., Checkpoint Therapeutic, Feldan Pharmaceuticals, Merck Pharmaceuticals. Serves as a Principal Investigator/Co-Investigator for: Regeneron (PI/Co-I), Merck (Co-I), Castle Biosciences (PI/Co-I). She is on the Board of Directors of Skin Cancer Outcomes Consortium (SCOUT); Koyfman: Advisory board (paid): Merck, BMS, Regeneron, Galera therapeutics; Advisory board (unpaid): Castle Biosciences; Research support: Castle biosciences, Merck, BMS, Regeneron; Honoraria: UpToDate; Vidimos: Research Support– Castle; Advisory Board - Inhibitor Therapeutics; Honoraria - Up to Date; Carucci: Receives funding for investigator initiated basic science research from Regeneron and is a PI for a clinical trial sponsored by Regeneron; Cañueto: Grants to institution: Sanofi/Regeneron, Castle-Biosciences; Lectures honoraria: Sanofi, Almirall, Abbvie, Regeneron, Sun Pharma; Payment for expert testimony: Sanofi, Regeneron, Almirall; Support for attending meetings: Pfyzer, Almirall, Lilly, Castle-Biosciences; Advisory board: Almirall, Sanofi, Regeneron, Kyowa, Roche, InflaRx; Funding: support by the Gerencia Regional de Salud de Castilla y León (GRS2549/A/22) and by the Instituto de Salud Carlos III (PI21/01207), co-financed by European Union; Mangold: Relevant disclosures patent Methods and Materials for assessing and treating cutaneous squamous cell carcinoma (provisional PCT/US2023/078902) and Regeneron Consulting with payments to the institution. He has consulted for Phelecs BV, Kyowa, Eli Lilly, Momenta, UCB, and Regeneron in the past, greater than 24 months ago. He has consulted for Incyte, Soligenix, Clarivate, Argenyx, and Bristol Myers Squibb in the past, less than 12 months ago. He consults for Nuvig, Tourmaline Bio, Janssen, Boehringer Ingelheim currently. He consults for Pfizer currently with payments to the institution. He has grant support from Kyowa, Miragen, Regeneron, Corbus, Pfizer, Incyte, Eli Lilly, Argenx, Palvella, Abbvie, Priovant, Merck in the last 24 months. Beyond 24 months, grant support has come from Sun Pharma, Elorac, Novartis, and Janssen. His current patents include Use of Oral Jaki in Lichen Planus- PCT/US2024/020149; and Topical Ruxolitinib in Lichen Planus- PCT/US2021/053149, 2023-520085, & 21805700.8, respectively; Wysong: Institutional research grant from Castle Biosciences; Carr: Investigator for Regeneron, no direct funds.

: The data for the 12-center, multinational CSCC database described in this protocol is not available to external investigators.